Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Smith & Nephew revenue growth tops full-year forecasts
(Sharecast News) - Medical device giant Smith & Nephew reported fourth-quarter revenue of $1.46bn on Tuesday, marking a 6.4% increase on an underlying basis compared to the prior year. The FTSE 100 company said that growth trend continued throughout the year, with full-year revenue hitting $5.56bn, up an underlying 7.2% and surpassing expectations.
Its orthopaedics segment saw 5.7% underlying growth, while the sports medicine and ENT division experienced 10% underlying growth, despite challenges posed by a sluggish Chinese market.
Advanced wound management maintained its momentum from the prior year, achieving 6.4% underlying revenue growth.
Smith & Nephew said its trading profit rose 7.6% on a reported basis to $970m, with a trading profit margin of 17.5%, in line with its guidance.
Operating profit for the year was reported at $425m, while the firm generated significant cash flow from operations of $829m.
Earnings per share reached 30.2 cents compared to 25.5 cents in the prior year, with the board declaring a full-year dividend of 37.5 cents per share, consistent with the dividend paid in 2022.
Looking ahead, Smith & Nephew said it was optimistic despite challenges such as continuing inflation and headwinds from China volume-based procurement within sports medicine joint repair.
The company said it expected positive operating leverage and benefits from its 12-point plan to offset those challenges.
For 2024, Smith & Nephew anticipated underlying revenue growth in the range of 5% to 6%, with a trading profit margin expected to be at least 18%.
The company's midterm targets remained unchanged.
"I am pleased with our overall performance in 2023, as our actions to transform Smith & Nephew have begun to translate into meaningful financial outcomes," said chief executive officer Deepak Nath.
"We delivered revenue growth ahead of guidance for the full year and made important improvements to our trading profit margin against a challenging macro-environment.
"Our 12-point plan is on track - while there is more to do to enhance our performance in US reconstruction, our orthopaedics business is progressing along a clear improvement path. 2023 was another year of good growth for our Sports medicine and ENT and advanced wound management businesses."
Nath said the company's investment in innovation was delivering, with almost half of its 2023 growth coming from products launched in the last five years.
"We were pleased to add major launches in robotics, shoulder arthroplasty and negative pressure wound therapy to the portfolio during the year.
"We have entered 2024 as a fundamentally stronger business and look forward to delivering another year of robust growth and further margin expansion."
At 0813 GMT, shares in Smith & Nephew were up 4.31% at 1,174p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.